SymBio Pharmaceuticals Limited (SYMQY PINK) stock market data APIs

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and sales of pharmaceuticals and related operations to treat cancer, hematology, and viral infectious diseases in Japan and internationally. It offers SyB L-0501, an anti-cancer agent for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administration under the TREAKISYM name. The company also engages in the development of SyB L-1101, an intravenous formulation, which completed Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II clinical trial in combination with AZA to treat HR-MDS. In addition, it is involved in the development SyB V-1901, an antiviral drug. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.